

*Name:* National Advisory Council on Nurse Education and Practice (NACNEP).

*Dates and Times:* November 3, 2004, 8:30 a.m.–5 p.m.; November 4, 2004, 8:30 a.m.–5 p.m.; November 5, 2004, 8:30 a.m.–3 p.m.

*Place:* The St. Regis Hotel, 923 16th Street, NW., Washington, DC 20006.

*Status:* The meeting will be open to the public.

*Agenda:* Agency and Bureau administrative updates will be provided. The purpose of the meeting is to continue the April 2004 meeting focusing on geriatrics with implications for the nursing workforce, education and practice. While the April meeting focused on geriatric nursing workforce issues, geriatric nursing practice and education will be highlighted in this meeting. An opening presentation will provide a comprehensive view of patient safety in long-term care to be followed by a panel presentation of Health Resources and Services Administration, Bureau of Health Professions (BHP), geriatric exemplars. Additional presentations will highlight culturally competent care from the consumers' perspective and geriatric nursing education addressing models, gaps and implications for the future. An update of BHP's performance measures will also be presented. Work group discussions will take place on the first and second days to develop recommendations related to geriatrics. On the third day the Council will review a draft of the Fourth Report to the Secretary, HHS, and Congress and finalize all geriatrics recommendations from the April 2004 and the November 2004 meetings on nursing workforce, education and practice.

#### FOR FURTHER INFORMATION CONTACT:

Anyone interested in obtaining a roster of members, minutes of the meeting, or other relevant information should write or contact Ms. Elaine G. Cohen, M.S., R.N., Executive Secretary, National Advisory Council on Nurse Education and Practice, Parklawn Building, Room 9–35, 5600 Fishers Lane, Rockville, Maryland 20857, telephone (301) 443–1405.

Dated: October 14, 2004.

**Tina M. Cheatham,**

*Director, Division of Policy Review and Coordination.*

[FR Doc. 04–23627 Filed 10–21–04; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S.

Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: (301) 496–7057; fax: (301) 402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

#### Inhibitors of HIV Ribonuclease H Antiviral Properties

Drs. John Beutler, Stuart LeGrice, Scott Budihis, Antony Wamiru, Roberta Gardella, and Jennifer Wilson (all of NCI); Dr. Michael Parniak (EM) U.S. Provisional Application filed 30 Aug 2004 (DHHS Reference No. E–256–2004/0–US–01)

*Licensing Contact:* Sally Hu; 301/435–5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

The invention describes a class of compounds that inhibit HIV RNase H and the methods of using these compounds for the treatment of HIV infections. More specifically, these compounds are vinyllogous urea derivative containing substituted thiophene core structures and these compounds were part of the 100,000 member library of compounds purchased by NCI from ChemBridge. The selectivity of the antiviral activity was demonstrated in their selective inhibition of HIV–1 and HIV–2 Rnase H enzymes 1 in the CEM cell line of CD4+ lymphoblast cells. Five members of this class of compounds were able to block the cytopathic effect of the virus at concentrations that did not inhibit cell growth. Thus, these compounds may be used in the development of therapeutics for the treatment of retroviral infections, such as AIDS. In addition, these compounds described in this invention may also have particular value when used in combination treatments with other antiviral therapies directed at other viral targets, such as protease and integrase.

#### Protozoan Derived Antagonist of CCR5

Drs. Alan Sher, Julio Aliberti, Jose Ribeiro, and John Andersen (all of NIAID); Dr. Hana Golding (FDA)

U.S. Provisional Application No. 60/586,884 filed 08 Jul 2004 (DHHS Reference No. E–272–2004/0–US–01) *Licensing Contact:* Sally Hu; 301/435–5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

The invention describes the anti-HIV properties of cyclophilin-18, a protein expressed by the protozoan parasite *Toxoplasma gondii*. The protein was found to bind to the chemokine receptor CCR5 which is also a co-receptor for the HIV virus. Both the native and recombinant molecules display inhibitory activity in HIV–1 fusion (syncytia formation) and infectivity assays with human T cells and macrophages. Thus, *Toxoplasma gondii* cyclophilin-18 or modified versions of the molecule may be used in the development of treatment for AIDS. In particular, the protein described in this invention may have particular value when used as a microbicide for blocking initial HIV infection. More details of this invention can be found in Golding et al., “Inhibition of HIV–1 Infection by a CCR5 Binding Cyclophilin from *Toxoplasma gondii*”, *Blood* 1 Nov 2003 102(9): 3280–3286.

#### Treatment of Human Viral Infections (Resveratrol)

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI)

U.S. Provisional Application No. 60/588,013 filed 13 Jul 2004 (DHHS Reference No. E–279–2004/0–US–01) *Licensing Contact:* Sally Hu; 301/435–5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

This application describes the methods for treating or preventing an HIV infection by the administration of an Egr 1 activator called Resveratrol (3, 5, 4"-trihydroxystilbene) and its derivatives. It has been known that HIV, once it infects a cell, integrates into the cellular genome and can (1) rapidly undergo lytic infection, or (2) lay dormant for a period of time (latent infection). The existence of latent infected cells poses a great challenge to HIV therapy because (1) there are no good existing means that can separate the latent infected cells from the uninfected cells; (2) even when antiretroviral drugs are able to completely suppress detectable HIV replication, these latent infected cells will remain and HIV can subsequently complete the viral replication cycle to produce more virus. Since Resveratrol and its derivatives can activate lytic replication from latent infected cells via its effects on Erk1/2 signaling, Resveratrol and its derivatives may lead to therapies in which Resveratrol and/or its derivatives is given together with highly active antiretroviral therapy in an

effort to decrease or eliminate the reservoir of latent infected cells with hope of perhaps eventually curing a patient of HIV infection.

#### **Treatment of Human Viral Infections (Proteasome Inhibitors)**

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI)  
U.S. Provisional Application No. 60/587,810 filed 13 Jul 2004 (DHHS Reference No. E-280-2004/0-US-01)  
*Licensing Contact:* Sally Hu; 301/435-5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

This application describes the methods for treating or preventing an HIV infection by the administration of proteasome inhibitors and their derivatives. It has been known that HIV, once it infects a cell, integrates into the cellular genome and can (1) rapidly undergo lytic infection, or (2) lay dormant for a period of time (latent infection). The existence of latent infected cells poses a great challenge to HIV therapy because (1) there are no good existing means that can separate the latent infected cells from the uninfected cells; (2) even when antiretroviral drugs are able to completely suppress detectable HIV replication, these latent infected cells will remain and HIV can subsequently complete the viral replication cycle to produce more virus. Since proteasome inhibitors can activate lytic replication from latent infected cells, proteasome inhibitors may lead to therapies in which proteasome inhibitors are given together with highly active antiretroviral therapy in an effort to decrease or eliminate the reservoir of latent infected cells with hope of perhaps eventually curing a patient of HIV infection.

#### **Treatment of Human Viral Infections (Imatinib)**

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI)  
U.S. Provisional Application No. 60/588,015 filed 13 Jul 2004 (DHHS Reference No. E-281-2004/0-US-01)  
*Licensing Contact:* Sally Hu; 301/435-5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

This application describes the methods for treating or preventing an HIV infection by the administration of abl-kinase inhibitor called imatinib and its derivatives. It has been known that HIV, once it infects a cell, integrates into the cellular genome and can (1) rapidly undergo lytic infection, or (2) lay dormant for a period of time (latent infection). The existence of latent infected cells poses a great challenge to HIV therapy because (1) there are no good existing means that can separate the latent infected cells from the

uninfected cells; (2) even when antiretroviral drugs are able to completely suppress detectable HIV replication, these latent infected cells will remain and HIV can subsequently complete the viral replication cycle to produce more virus. Since imatinib and its derivatives can activate lytic replication from latent infected cells by activating NF- $\kappa$ B, imatinib and its derivatives may lead to therapies in which imatinib and/or its derivatives is given together with highly active antiretroviral therapy in an effort to decrease or eliminate the reservoir of latent infected cells with hope of perhaps eventually curing a patient of HIV infection.

#### **Treatment of Human Viral Infections (Farnesyl Transferase Inhibitors)**

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI)  
U.S. Provisional Application No. 60/587,771 filed 13 Jul 2004 (DHHS Reference No. E-282-2004/0-US-01)  
*Licensing Contact:* Sally Hu; 301/435-5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

This application describes the methods for treating or preventing an HIV infection by the administration of farnesyl transferase inhibitors such as FTI277, L-744832, BMS214662, R115777 and SCH66336. It has been known that HIV, once it infects a cell, integrates into the cellular genome and can (1) rapidly undergo lytic infection, or (2) lay dormant for a period of time (latent infection). The existence of latent infected cells poses a great challenge to HIV therapy because (1) there are no good existing means that can separate the latent infected cells from the uninfected cells; (2) even when antiretroviral drugs are able to completely suppress detectable HIV replication, these latent infected cells will remain and HIV can subsequently complete the viral replication cycle to produce more virus. Since farnesyl transferase inhibitors can activate lytic replication from latent infected cells by modulating membrane-bound Ras-Rho levels, farnesyl transferase inhibitors may lead to therapies in which farnesyl transferase inhibitor is given together with highly active antiretroviral therapy in an effort to decrease or eliminate the reservoir of latent infected cells with hope of perhaps eventually curing a patient of HIV infection.

Dated: October 15, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-23650 Filed 10-21-04; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute on Drug Abuse; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel. Member Conflict Meeting.

*Date:* November 17, 2004.

*Time:* 6 p.m. to 8 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.

*Contact Person:* Mark Swieter, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Suite 220, Bethesda, MD 20892-8401, (301) 435-1389.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: October 14, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-23654 Filed 10-21-04; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of General Medical Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.